The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The research target has been confirmed as human MYD88 (UniProt: Q99836), encoding the myeloid differentiation primary response protein MyD88. The protein contains the expected domain architecture including a DEATH-like domain superfamily region, Death domain (IPR000488), MyD88 Death domain (IPR034249), and TIR domain (IPR000157), consistent with the UniProt annotation for Homo sapiens (song2024myd88andits pages 1-2, pustelny2022mechanismofmyd88s pages 1-2).
Human MYD88 functions as a critical cytoplasmic adaptor protein that links activated innate immune receptors—particularly Toll-like receptors (TLRs) and interleukin-1 receptor family members (IL-1R, IL-18R)—to downstream signaling kinases and transcription factors (song2024myd88andits pages 2-4, song2024myd88andits pages 1-2, rughetti2024imperativeroleof pages 5-6). Unlike enzymes that catalyze biochemical reactions with specific substrates, MYD88 operates as a non-enzymatic scaffold protein that organizes proximity-driven signaling complexes (song2024myd88andits pages 2-4, pustelny2022mechanismofmyd88s pages 1-2).
MYD88 mediates signaling from nearly all TLRs except TLR3, which uses the alternative TRIF adaptor (song2024myd88andits pages 2-4, rughetti2024imperativeroleof pages 3-5, rughetti2024imperativeroleof pages 5-6). Following receptor engagement by pathogen-associated or damage-associated molecular patterns, MYD88 is recruited to the receptor's intracellular TIR domain and nucleates formation of a supramolecular organizing center called the "myddosome" (pustelny2022mechanismofmyd88s pages 1-2, pereira2023regulationofinnate pages 2-4).
MYD88 consists of three functionally distinct domains that cooperate to transduce receptor signals:
| MYD88 region | Approximate residues in human MYD88L | Structural characteristics | Primary function in signaling | Key experimental or mechanistic features |
|---|---|---|---|---|
| N-terminal death domain (DD) | 1–109; experimentally defined folded core approximately Arg20–Ala104 | Death-domain superfamily module specialized for homotypic and heterotypic protein–protein interactions | Oligomerizes with other MYD88 DDs and recruits the DDs of IRAK4, followed by IRAK1 and/or IRAK2, thereby building the kinase-recruiting core of the myddosome | MYD88 DD oligomerization determines myddosome architecture. MYD88 and IRAK DDs form a layered, left-handed helical assembly that promotes IRAK4 trans-autophosphorylation and downstream IRAK1/2 activation; reported complexes commonly contain approximately 6–8 MYD88 and four IRAK4 molecules (gurkan2024theirakmdeath pages 1-2, pereira2023regulationofinnate pages 2-4, gurkan2024theirakmdeath pages 8-10) |
| Intermediate domain (ID/INT) | 110–155; approximately 46 amino acids | Largely intrinsically disordered linker between the DD and TIR domain, with transient secondary structure | Supports productive myddosome nucleation, complex growth, IRAK4 recruitment or activation, and NF-κB signal propagation; it is therefore more than a passive linker | Residues Gln114–Leu118, especially Tyr116, are critical for productive myddosome assembly. The short splice isoform MYD88S, which lacks this region, can enter nascent complexes but prevents their maturation and acts as a dominant-negative regulator (pustelny2022mechanismofmyd88s pages 1-2, pustelny2022mechanismofmyd88s pages 2-4, pustelny2022mechanismofmyd88s pages 9-11) |
| C-terminal Toll/interleukin-1 receptor domain (TIR) | 156–296 | Flavodoxin-like TIR fold containing signaling surfaces and a functionally important BB loop | Engages TIR domains of activated Toll-like and IL-1 receptor-family receptors, either directly or through TIRAP/MAL, and nucleates higher-order MYD88 assembly at receptor-proximal signaling sites | Recent structural work shows two offset, parallel, head-to-tail MYD88-TIR strands stabilized by asymmetric BE intrastrand and BCD interstrand interfaces. A 2024 TLR2-nucleated MicroED structure resolved this assembly at 2.85 Å and revealed signaling-associated rearrangements in the B helix, BB loop, and CD loop (bhatt2024structuralcharacterizationof pages 2-3, bhatt2024structuralcharacterizationof pages 7-8, li2024microcrystalelectrondiffraction pages 1-2, li2024microcrystalelectrondiffraction pages 8-11) |
| Integrated full-length architecture | 1–296 | Modular DD–ID–TIR adaptor; not an enzyme and has no catalytic substrate | Converts receptor activation into proximity-driven assembly of the MYD88–IRAK4–IRAK1/2 myddosome, ultimately activating NF-κB, MAPK/AP-1, and receptor-context-dependent IRF signaling | Functional sequence: receptor TIR engagement → cooperative MYD88-TIR assembly → DD-mediated myddosome formation → IRAK recruitment and activation → TRAF6–TAK1 signaling. The oncogenic L265P substitution lies in the TIR domain and promotes constitutive aggregation and signaling (pustelny2022mechanismofmyd88s pages 1-2, vegivinti2023roleofinnate pages 1-3, song2024myd88andits pages 1-2, minderman2023theoncogenichuman pages 8-9) |
Table: This table maps the three principal domains of human MYD88L to their approximate residue boundaries, structural properties, and signaling functions. It also summarizes experimental evidence connecting each region to receptor recruitment, myddosome assembly, and downstream signal propagation.
N-terminal Death Domain (DD; residues ~1-109): The death domain mediates homotypic protein-protein interactions with other MYD88 molecules and heterotypic interactions with the death domains of IL-1 receptor-associated kinases (IRAKs), particularly IRAK4 and IRAK1/2 (pustelny2022mechanismofmyd88s pages 1-2, gurkan2024theirakmdeath pages 1-2). Through these interactions, the DD constructs the core oligomeric scaffold of the myddosome. Structural studies reveal that the myddosome assembles as a layered, left-handed helical complex typically containing approximately 6-8 MyD88 molecules associating with four IRAK4 molecules (pereira2023regulationofinnate pages 2-4, gurkan2024theirakmdeath pages 8-10).
Intermediate Domain (ID; residues ~110-155): Initially thought to be merely a passive linker, the 46-amino-acid intermediate domain is largely intrinsically disordered yet plays an essential regulatory role in myddosome nucleation and signal propagation (pustelny2022mechanismofmyd88s pages 1-2, pustelny2022mechanismofmyd88s pages 2-4). Residues Gln114-Leu118, particularly Tyr116, are critical for productive myddosome assembly and IRAK4 activation (pustelny2022mechanismofmyd88s pages 2-4, pustelny2022mechanismofmyd88s pages 12-14, pustelny2022mechanismofmyd88s pages 9-11). The alternatively spliced isoform MyD88S, which lacks the intermediate domain, can be incorporated into nascent signaling complexes but prevents their maturation, thereby acting as a dominant-negative regulator that terminates inflammatory signaling (pustelny2022mechanismofmyd88s pages 1-2, pustelny2022mechanismofmyd88s pages 9-11).
C-terminal TIR Domain (residues ~156-296): The Toll/interleukin-1 receptor (TIR) domain adopts a flavodoxin-like fold and engages the TIR domains of activated receptors, either directly or through bridging adaptors such as TIRAP/MAL (saikh2024targetingmyeloiddifferentiation pages 2-4, bhatt2024structuralcharacterizationof pages 2-3, rughetti2024imperativeroleof pages 5-6). The TIR domain's BB loop is functionally critical for TIR-TIR homotypic interactions that drive MyD88 oligomerization (saikh2024targetingmyeloiddifferentiation pages 2-4).
Recent structural and mechanistic studies have elucidated the stepwise process of myddosome formation:
Receptor Nucleation: Ligand-induced receptor dimerization or oligomerization triggers conformational changes in receptor cytoplasmic TIR domains, creating high-affinity binding sites for MYD88 TIR domains (pustelny2022mechanismofmyd88s pages 1-2, pereira2023regulationofinnate pages 2-4, song2024myd88andits pages 2-4).
TIR-Domain Assembly: MYD88 TIR domains assemble into two-stranded, parallel, head-to-tail filamentous structures. A landmark 2024 microcrystal electron diffraction (MicroED) study resolved the TLR2-nucleated MyD88 TIR assembly at 2.85 Å resolution, revealing that assembly is stabilized by asymmetric intrastrand BE interfaces and lateral interstrand BCD interfaces (li2024microcrystalelectrondiffraction pages 8-11, bhatt2024structuralcharacterizationof pages 7-8, li2024microcrystalelectrondiffraction pages 1-2). The EE surface of incoming MyD88 molecules binds the BB surface of already-oligomerized subunits, driving conformational rearrangement of the B helix and BB loop and supporting unidirectional elongation (li2024microcrystalelectrondiffraction pages 8-11).
Progressive Oligomerization: MyD88 molecules initially form small, unstable oligomers that grow progressively with continued receptor stimulation (pereira2023regulationofinnate pages 2-4, song2024myd88andits pages 2-4). Once the oligomer reaches a critical size threshold, it establishes stable interactions with IRAK4 (song2024myd88andits pages 2-4).
IRAK Recruitment and Activation: The assembled MyD88 death domains recruit four IRAK4 molecules, followed by IRAK1 and/or IRAK2, creating a three-layered helical signaling complex (gurkan2024theirakmdeath pages 1-2, pereira2023regulationofinnate pages 2-4, gurkan2024theirakmdeath pages 8-10). Proximity within this structure enables IRAK4 molecules to trans-autophosphorylate and subsequently phosphorylate and activate IRAK1/2 (pereira2023regulationofinnate pages 2-4, vegivinti2023roleofinnate pages 1-3).
Downstream Signaling Initiation: Activated IRAK1 dissociates from the myddosome and engages the E3 ubiquitin ligase TRAF6, initiating the downstream TAK1-IKK-NF-κB and MAPK cascades (vegivinti2023roleofinnate pages 1-3, pereira2023regulationofinnate pages 6-7).
MYD88 is a cytoplasmic/cytosolic protein that carries out its signaling function at receptor-associated sites (song2024myd88andits pages 1-2, rughetti2024imperativeroleof pages 5-6, pustelny2022mechanismofmyd88s pages 1-2). In its basal state, MYD88 resides in the cytoplasm. Upon receptor activation, it is recruited to the intracellular domains of TLRs and IL-1R family members at cellular membranes, where it assembles into functional myddosome signaling complexes (rughetti2024imperativeroleof pages 5-6, pustelny2022mechanismofmyd88s pages 1-2, pustelny2022mechanismofmyd88s pages 11-12). The myddosome forms at membrane-proximal sites for plasma-membrane receptors (TLR2, TLR4, TLR5, IL-1R) or at endosomal membranes for intracellular TLRs (TLR7, TLR8, TLR9) that detect nucleic acids (rughetti2024imperativeroleof pages 5-6).
| Upstream receptor(s) | Typical ligand and location | MYD88 recruitment | Core downstream signaling | Principal transcriptional outputs | MYD88 dependence |
|---|---|---|---|---|---|
| TLR1/TLR2 and TLR2/TLR6 | Microbial lipoproteins; plasma membrane | Indirect, principally through TIRAP/MAL, which bridges receptor and MYD88 TIR domains | MYD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKK and MAPK cascades | NF-κB and AP-1; inflammatory cytokines and chemokines | MYD88-dependent (rughetti2024imperativeroleof pages 3-5, rughetti2024imperativeroleof pages 5-6, vegivinti2023roleofinnate pages 1-3) |
| TLR4 | Bacterial LPS; plasma membrane followed by endocytosis | Plasma-membrane recruitment through TIRAP/MAL | MYD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKK and MAPKs | Early NF-κB and AP-1 activation; TNF, IL-6, and other inflammatory mediators | Uses an early MYD88-dependent branch and a separate endosomal TRAM–TRIF branch that activates IRF3, type-I interferon, and later NF-κB (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5, pereira2023regulationofinnate pages 6-7) |
| TLR5 | Bacterial flagellin; plasma membrane | Generally direct receptor–MYD88 recruitment; some reviews describe context-dependent TIRAP participation | MYD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 | NF-κB and MAPK/AP-1; inflammatory cytokines | MYD88-dependent (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5, rughetti2024imperativeroleof pages 2-3) |
| TLR7 and TLR8 | Single-stranded RNA; endosomes | Direct recruitment to activated receptor TIR domains | MYD88 → IRAK4 → IRAK1/2; TRAF6–TAK1 inflammatory arm with receptor- and cell-specific IRF engagement | NF-κB, MAPK/AP-1, and IRF5/IRF7-associated inflammatory or interferon programs | MYD88-dependent (rughetti2024imperativeroleof pages 5-6) |
| TLR9 | Unmethylated CpG-rich DNA; endosomes | Direct recruitment of MYD88 | MYD88 → IRAK4 → IRAK1/2; TRAF6–TAK1 and IRF7-associated signaling | NF-κB/MAPK inflammatory genes; IRF7-dependent type-I interferon, especially in plasmacytoid dendritic cells | MYD88-dependent (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5, song2024myd88andits pages 1-2) |
| IL-1R family, including IL-1R and IL-18R | IL-1-family cytokines; plasma membrane | Direct TIR-domain coupling after receptor–coreceptor assembly | MYD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKK and MAPKs | NF-κB and AP-1; inflammatory gene expression | MYD88-dependent (song2024myd88andits pages 1-2, pereira2023regulationofinnate pages 12-12, pereira2023regulationofinnate pages 2-4) |
| TLR3 | Double-stranded RNA; endosomes | Does not recruit MYD88; recruits TRIF directly | TRIF → TBK1/IKKε and TRAF-associated signaling | IRF3/type-I interferon and NF-κB | MYD88-independent; the principal exception among human TLRs (rughetti2024imperativeroleof pages 3-5) |
| Shared myddosome mechanism | Activated MYD88-using TLR or IL-1R-family receptor | Receptor TIR domains nucleate MYD88 oligomerization directly or through TIRAP | Approximately 6–8 MYD88 molecules recruit about four IRAK4 molecules, followed by IRAK1/2; IRAK activation engages TRAF6 and TAK1 | IKK-mediated IκB degradation releases NF-κB; MAPKs activate AP-1; selected endosomal pathways engage IRF5/IRF7 | Converts receptor clustering into an amplified, proximity-driven inflammatory signaling platform (pereira2023regulationofinnate pages 2-4, vegivinti2023roleofinnate pages 1-3, pereira2023regulationofinnate pages 6-7) |
Table: This table maps human TLR and interleukin-receptor inputs to MYD88 recruitment, myddosome components, and downstream NF-κB, MAPK/AP-1, and IRF outputs. It distinguishes TLR3 and the TLR4 TRIF branch as MYD88-independent routes.
MYD88 functions downstream of most TLRs and the IL-1 receptor family:
Direct MYD88 Recruitment: TLR5, TLR7, TLR8, TLR9, IL-1R, and IL-18R directly recruit MYD88 through TIR-domain interactions (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5, song2024myd88andits pages 1-2).
TIRAP/MAL-Mediated Recruitment: TLR1/2, TLR2/6, and TLR4 require the bridging adaptor TIRAP (also called MAL) to facilitate MYD88 recruitment (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5).
TLR4 Dual Signaling: TLR4 is unique in engaging both MYD88-dependent and MYD88-independent pathways. At the plasma membrane, TLR4 signals through TIRAP-MYD88 to activate early NF-κB and inflammatory cytokines. After endocytosis, TLR4 switches to a TRAM-TRIF pathway that activates IRF3, type I interferons, and late NF-κB signaling (rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 3-5).
TLR3 Exception: TLR3 is the only TLR that does not use MYD88, instead recruiting TRIF directly to activate IRF3-dependent interferon responses (rughetti2024imperativeroleof pages 3-5).
MYD88-dependent signaling activates multiple transcription factor families:
NF-κB Pathway: IRAK1 activation leads to TRAF6-mediated K63-linked ubiquitination and activation of TAK1. TAK1 phosphorylates the IKK complex, which phosphorylates IκBα, triggering its proteasomal degradation and releasing NF-κB dimers (p50/p65) to translocate to the nucleus and induce inflammatory gene expression (vegivinti2023roleofinnate pages 1-3, song2024myd88andits pages 1-2, rughetti2024imperativeroleof pages 2-3).
MAPK/AP-1 Pathways: TAK1 also activates mitogen-activated protein kinase (MAPK) cascades including ERK, JNK, and p38, leading to AP-1 transcription factor activation and expression of inflammatory mediators (song2024myd88andits pages 1-2, rughetti2024imperativeroleof pages 5-6, rughetti2024imperativeroleof pages 2-3, pereira2023regulationofinnate pages 6-7).
Interferon Regulatory Factor Signaling: MYD88 can modulate interferon responses through multiple mechanisms. In plasmacytoid dendritic cells, TLR7 and TLR9 signaling recruits IRF7 to the myddosome, promoting type I interferon production (rughetti2024imperativeroleof pages 5-6, song2024myd88andits pages 1-2). MYD88 also regulates IRF5 activation in certain cell types (rughetti2024imperativeroleof pages 5-6, pereira2023regulationofinnate pages 6-7). Additionally, the MyD88 intermediate domain can mediate IRF-7 activity independently of death-domain folding (song2024myd88andits pages 2-4, song2024myd88andits pages 1-2).
Functional Outputs: These transcriptional programs induce production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), chemokines, type I and type III interferons, acute-phase proteins, and enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (song2024myd88andits pages 2-4, rughetti2024imperativeroleof pages 5-6).
A major advance in 2024 came from combined microcrystal electron diffraction (MicroED) and serial femtosecond crystallography studies that resolved MyD88 TIR-domain assemblies at near-atomic resolution (bhatt2024structuralcharacterizationof pages 7-8, bhatt2024structuralcharacterizationof pages 5-7, li2024microcrystalelectrondiffraction pages 1-2). These structures revealed that:
These findings support a nucleated hierarchical assembly model termed "signaling by cooperative assembly formation" (SCAF), in which receptor clustering overcomes the energetic barrier to forming open-ended TIR-domain assemblies that recruit downstream effectors (bhatt2024structuralcharacterizationof pages 8-10).
Recent studies (2023-2024) have identified regulatory mechanisms that fine-tune MyD88 activity:
Phosphorylation: A 2023 study demonstrated that MyD88 serine 257 (S257) phosphorylation promotes MyD88 aggregation, IRAK1 phosphorylation, and NF-κB activation. The oncogenic L265P mutation genocopies this phosphorylation-induced activation (minderman2023theoncogenichuman pages 8-9).
Acetylation: A 2024 study showed that upon LPS stimulation, the lysine acetyltransferase CBP acetylates TIR domains in the TLR4 signalosome, including MyD88, enhancing NF-κB signaling while having minimal effect on IRF3 pathways (saikh2024targetingmyeloiddifferentiation pages 4-5).
Ubiquitination: OTUD5 deubiquitinase cleaves K11-linked polyubiquitin chains on MyD88 at Lys95, Lys231, and Lys250, enhancing MyD88 oligomerization and myddosome formation after LPS stimulation (li2024microcrystalelectrondiffraction pages 8-11).
| Disease / clinical setting | MYD88 alteration and reported frequency | Biological or diagnostic significance | Prognostic / therapeutic implications |
|---|---|---|---|
| Waldenström macroglobulinemia (WM) / lymphoplasmacytic lymphoma | L265P in >90% of patients; approximately 91% in one review, leaving 5–10% MYD88-wild-type (WT) (bagratuni2023myd88wildtype pages 1-2, bagratuni2023myd88wildtype pages 4-5) | Hallmark driver and useful diagnostic biomarker, although not disease-specific. Constitutive MYD88 signaling promotes IRAK/BTK, NF-κB, BCL2, and tumor-cell survival pathways (tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 7-9, bagratuni2023myd88wildtype pages 2-4) | Genotype informs treatment selection, particularly expected response to BTK-pathway inhibition. WT disease has been associated with reduced response to some BTK inhibitors, greater transformation risk, and shorter overall survival (bagratuni2023myd88wildtype pages 1-2) |
| WM: mutant versus WT molecular phenotype | A 2024 single-cell study analyzed five L265P, two WT, and two healthy-donor samples; L265P occurs in >90% of WM overall (bagratuni2023myd88wildtype pages 1-2) | L265P and WT tumors exhibit distinct transcriptional programs involving NF-κB, BCL2, and BTK, with substantial intratumoral and interpatient heterogeneity | Molecular heterogeneity may explain variable prognosis and treatment response even among L265P-positive patients; genotype alone does not capture all relevant tumor biology |
| IgM monoclonal gammopathy of undetermined significance (IgM-MGUS) | L265P reported in approximately 50–80% of cases; one 2024 cohort found 60% (bagratuni2023myd88wildtype pages 4-5) | May arise early in clonal evolution and helps distinguish IgM-MGUS/WM biology from IgM myeloma. It is associated with increased progression risk, although most carriers do not progress (bagratuni2023myd88wildtype pages 4-5) | Potential risk-stratification biomarker, but insufficient alone to predict progression; additional genomic and clinical variables are required |
| IgM multiple myeloma and non-IgM MGUS | L265P is generally absent from IgM myeloma and IgG/IgA MGUS (bagratuni2023myd88wildtype pages 4-5) | Absence helps distinguish plasma-cell neoplasia from WM/LPL when clinicopathologic findings overlap; IgM myeloma is more often associated with t(11;14) |
Useful primarily for differential diagnosis rather than prognosis |
| Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) | Recurrent activating MYD88 mutations, especially L265P; uncommon in germinal-center B-cell-like DLBCL, but no single frequency applies across cohorts (bagratuni2023myd88wildtype pages 2-4) | Constitutive MYD88–IRAK–NF-κB signaling supports lymphoma-cell growth and survival; some tumors are functionally dependent on mutant MYD88 (minderman2023theoncogenichuman pages 8-9) | Establishes a targetable dependency involving the myddosome, IRAK kinases, BTK, and NF-κB. Prognostic effects vary by anatomic site, molecular subtype, and treatment context |
| Primary CNS, primary testicular, and other immune-privileged-site DLBCL | MYD88 mutations, including L265P, are enriched, although frequencies were not quantified in the reviewed evidence (bagratuni2023myd88wildtype pages 2-4, minderman2023theoncogenichuman pages 8-9) | Supports a shared oncogenic program centered on chronic MYD88 signaling and helps classify these extranodal lymphomas | May provide diagnostic support and identify patients for pathway-directed therapy; clinical value remains context-dependent |
| Primary cutaneous DLBCL, leg type | L265P is described as frequent and clinically relevant, without a numerical frequency in the reviewed evidence (tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 7-9, tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 9-11) | Supports classification as a MYD88-driven lymphoma and may help distinguish it from other cutaneous B-cell neoplasms | Reported to carry prognostic value, but its direction and magnitude require interpretation within disease-specific cohorts |
| Marginal-zone lymphoma (MZL), particularly IgM-secreting cases | L265P occurs in a minority of cases; prevalence varies by MZL subtype (bagratuni2023myd88wildtype pages 4-5) | Demonstrates that L265P is not specific to WM; mutation results must be integrated with morphology, immunophenotype, paraprotein, and clinical distribution | Limited standalone prognostic value; used principally in differential diagnosis with other disease features |
| Other mature B-cell neoplasms | Lower-frequency MYD88 mutations occur in chronic lymphocytic leukemia and splenic MZL; they are rare in hairy-cell leukemia, Burkitt lymphoma, and follicular lymphoma and appear absent from some entities such as primary mediastinal B-cell lymphoma (bagratuni2023myd88wildtype pages 1-2, bagratuni2023myd88wildtype pages 4-5) | MYD88 activation is concentrated in particular B-cell differentiation states and lymphoma subtypes rather than being a universal cancer event | Clinical significance is disease-specific; low prevalence limits use as a universal prognostic biomarker |
| Non-L265P MYD88-mutant IgM gammopathies / lymphomas | Reported variants include M232T, S243N, S222R, T294P, and S219C; frequencies are low or incompletely defined (bagratuni2023myd88wildtype pages 2-4) | Some variants may activate MYD88 signaling, but their functional strength and diagnostic specificity are less established than those of L265P | These variants should not automatically be interpreted as equivalent to L265P; functional annotation and disease context are necessary |
| MYD88-WT WM / IgM gammopathy | Approximately 5–10% of WM lacks L265P or another detectable MYD88 mutation (bagratuni2023myd88wildtype pages 1-2, bagratuni2023myd88wildtype pages 4-5) | WT status does not exclude WM but may define a biologically distinct subgroup; exclusion of mimics and confirmation with sensitive testing are important | Associated in several studies with greater transformation risk, resistance to some therapies, reduced BTK-inhibitor responsiveness, and shorter survival relative to mutant disease (bagratuni2023myd88wildtype pages 1-2) |
Table: This table summarizes MYD88 alterations—especially L265P—across WM, DLBCL, related lymphomas, and precursor gammopathies. It compares reported frequencies, diagnostic relevance, and the clinical distinctions between MYD88-mutant and wild-type disease.
The most clinically significant MYD88 alteration is the somatic L265P mutation (leucine to proline at position 265 in the TIR domain), which drives several B-cell malignancies:
Waldenström Macroglobulinemia (WM): The L265P mutation occurs in >90% of WM cases, a lymphoplasmacytic lymphoma characterized by IgM monoclonal protein secretion (bagratuni2023myd88wildtype pages 2-4, bagratuni2023myd88wildtype pages 1-2, bagratuni2023myd88wildtype pages 4-5, lemasson2023bcellspecificexpression pages 1-6). This mutation serves as a key diagnostic biomarker and driver of disease pathogenesis (tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 7-9, bagratuni2023myd88wildtype pages 2-4). The mutation promotes constitutive MYD88 aggregation, IRAK/BTK pathway activation, NF-κB signaling, and B-cell survival (tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 7-9, bagratuni2023myd88wildtype pages 2-4, minderman2023theoncogenichuman pages 8-9).
Diffuse Large B-Cell Lymphoma (DLBCL): L265P is enriched in activated B-cell-like (ABC) DLBCL and is particularly frequent in primary CNS, primary testicular, and primary cutaneous DLBCL leg-type (bagratuni2023myd88wildtype pages 2-4, song2024myd88andits pages 2-4, tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 9-11, minderman2023theoncogenichuman pages 8-9). The mutation creates oncogenic addiction to MYD88-IRAK-BTK-NF-κB signaling (minderman2023theoncogenichuman pages 8-9).
IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS): L265P is present in 50-80% of IgM-MGUS cases and is associated with increased risk of progression to WM, although most carriers do not progress (bagratuni2023myd88wildtype pages 4-5).
MYD88 Wild-Type Disease: Approximately 5-10% of WM patients lack the L265P mutation. MYD88 wild-type (WT) WM is associated with higher risk of transformation to aggressive lymphoma, reduced responsiveness to BTK inhibitors, and shorter overall survival compared to L265P-positive disease (bagratuni2023myd88wildtype pages 1-2, bagratuni2023myd88wildtype pages 4-5).
Molecular Heterogeneity: A 2024 single-cell RNA sequencing study of WM patients revealed substantial intra-tumor and inter-patient transcriptional heterogeneity even among L265P-positive cases, with distinct gene expression signatures affecting NF-κB, BCL2, and BTK pathways (bagratuni2023myd88wildtype pages 2-4).
Therapeutic Targeting: The central role of MYD88 in lymphoma cell survival has prompted development of targeted therapies, including:
- Small molecule inhibitors of MYD88 dimerization (e.g., ST2825) that disrupt myddosome assembly (song2024myd88andits pages 2-4)
- BTK inhibitors (e.g., ibrutinib) that target downstream signaling in MYD88-mutant tumors
- Compounds targeting the TIR domain BB-loop interactions to reduce inflammatory signaling (saikh2024targetingmyeloiddifferentiation pages 2-4, saikh2024targetingmyeloiddifferentiation pages 4-5)
Beyond cancer, excessive MYD88 signaling contributes to various inflammatory conditions. Targeting MYD88 has shown promise in preclinical models of:
- Rheumatoid arthritis, where ST2825 reduced synovial fibroblast proliferation and invasiveness (song2024myd88andits pages 2-4)
- Sepsis and acute lung injury, where MYD88 inhibition modulated cytokine storm responses (saikh2024targetingmyeloiddifferentiation pages 2-4)
- Viral infections including SARS-CoV-2, where MYD88 upregulation may impair type I interferon responses (saikh2024targetingmyeloiddifferentiation pages 2-4, saikh2024targetingmyeloiddifferentiation pages 4-5)
Human MYD88 functions as a pivotal cytoplasmic adaptor protein in innate immunity, linking activated pattern-recognition receptors to inflammatory signaling cascades. Its primary role is to scaffold the myddosome, a supramolecular signaling complex that amplifies receptor-derived signals through IRAK kinases, TRAF6, and downstream NF-κB, MAPK, and IRF pathways. MYD88 does not possess enzymatic activity or substrate specificity in the traditional sense; rather, it organizes proximity-driven protein interactions that enable signal transduction.
The protein's modular domain architecture—comprising an N-terminal death domain, intermediate domain, and C-terminal TIR domain—supports sequential receptor engagement, oligomerization, and kinase recruitment. Recent structural advances in 2024 have provided near-atomic resolution views of TIR-domain assembly, revealing the molecular basis for cooperative signaling complex formation.
Clinically, the oncogenic L265P mutation in the TIR domain drives >90% of Waldenström macroglobulinemia cases and substantial fractions of aggressive B-cell lymphomas, establishing MYD88 as both a diagnostic biomarker and therapeutic target. Current research focuses on developing selective inhibitors of MYD88 dimerization and downstream signaling to treat both malignant and inflammatory diseases.
The evidence presented here derives primarily from peer-reviewed publications from 2022-2024, with particular emphasis on recent structural, mechanistic, and clinical studies that have advanced understanding of MYD88 biology and its role in human disease.
Key References:
- Song et al. (2024). MyD88 and Its Inhibitors in Cancer: Prospects and Challenges. Biomolecules 14(5):562.
- Li et al. (2024). Microcrystal electron diffraction structure of Toll-like receptor 2 TIR-domain-nucleated MyD88 TIR-domain higher-order assembly. Acta Crystallographica Section D 80:699-712.
- Pereira & Gazzinelli (2023). Regulation of innate immune signaling by IRAK proteins. Frontiers in Immunology 14:1133354.
- Bagratuni et al. (2023). MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges. Hemato 4:259-272.
- Pustelny et al. (2022). Mechanism of MyD88S mediated signal termination. Cell Communication and Signaling 20:1.
References
(song2024myd88andits pages 1-2): Jiali Song, Yuying Li, Ke Wu, Yan Hu, and Luo Fang. Myd88 and its inhibitors in cancer: prospects and challenges. May 2024. URL: https://doi.org/10.3390/biom14050562, doi:10.3390/biom14050562. This article has 36 citations.
(pustelny2022mechanismofmyd88s pages 1-2): Katarzyna Pustelny, Katarzyna Kuska, Andrzej Gorecki, Bogdan Musielak, Ewelina Dobosz, Benedykt Wladyka, Joanna Koziel, Anna Czarna, Tad Holak, and Grzegorz Dubin. Mechanism of myd88s mediated signal termination. Cell Communication and Signaling, Jan 2022. URL: https://doi.org/10.1186/s12964-021-00811-1, doi:10.1186/s12964-021-00811-1. This article has 32 citations and is from a peer-reviewed journal.
(song2024myd88andits pages 2-4): Jiali Song, Yuying Li, Ke Wu, Yan Hu, and Luo Fang. Myd88 and its inhibitors in cancer: prospects and challenges. May 2024. URL: https://doi.org/10.3390/biom14050562, doi:10.3390/biom14050562. This article has 36 citations.
(rughetti2024imperativeroleof pages 5-6): Aurelia Rughetti, Shreya Bharti, Rajkumar Savai, Spyridoula Barmpoutsi, Andreas Weigert, Rajat Atre, Faaiza Siddiqi, Rahul Sharma, Rakhi Khabiya, Nik Hirani, and Mirza S Baig. Imperative role of adaptor proteins in macrophage toll-like receptor signaling pathways. Future science OA, 10 1:2387961, Sep 2024. URL: https://doi.org/10.1080/20565623.2024.2387961, doi:10.1080/20565623.2024.2387961. This article has 3 citations.
(rughetti2024imperativeroleof pages 3-5): Aurelia Rughetti, Shreya Bharti, Rajkumar Savai, Spyridoula Barmpoutsi, Andreas Weigert, Rajat Atre, Faaiza Siddiqi, Rahul Sharma, Rakhi Khabiya, Nik Hirani, and Mirza S Baig. Imperative role of adaptor proteins in macrophage toll-like receptor signaling pathways. Future science OA, 10 1:2387961, Sep 2024. URL: https://doi.org/10.1080/20565623.2024.2387961, doi:10.1080/20565623.2024.2387961. This article has 3 citations.
(pereira2023regulationofinnate pages 2-4): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 164 citations and is from a peer-reviewed journal.
(gurkan2024theirakmdeath pages 1-2): Berke Gürkan, Hessel Poelman, Liza Pereverzeva, Danielle Kruijswijk, Alex F. de Vos, Anouk G. Groenen, Edgar E. Nollet, Kanin Wichapong, Esther Lutgens, Tom van der Poll, Jiangfeng Du, W. Joost Wiersinga, Gerry A. F. Nicolaes, and Cornelis van ‘t Veer. The irak-m death domain: a tale of three surfaces. Frontiers in Molecular Biosciences, Jan 2024. URL: https://doi.org/10.3389/fmolb.2023.1265455, doi:10.3389/fmolb.2023.1265455. This article has 7 citations.
(gurkan2024theirakmdeath pages 8-10): Berke Gürkan, Hessel Poelman, Liza Pereverzeva, Danielle Kruijswijk, Alex F. de Vos, Anouk G. Groenen, Edgar E. Nollet, Kanin Wichapong, Esther Lutgens, Tom van der Poll, Jiangfeng Du, W. Joost Wiersinga, Gerry A. F. Nicolaes, and Cornelis van ‘t Veer. The irak-m death domain: a tale of three surfaces. Frontiers in Molecular Biosciences, Jan 2024. URL: https://doi.org/10.3389/fmolb.2023.1265455, doi:10.3389/fmolb.2023.1265455. This article has 7 citations.
(pustelny2022mechanismofmyd88s pages 2-4): Katarzyna Pustelny, Katarzyna Kuska, Andrzej Gorecki, Bogdan Musielak, Ewelina Dobosz, Benedykt Wladyka, Joanna Koziel, Anna Czarna, Tad Holak, and Grzegorz Dubin. Mechanism of myd88s mediated signal termination. Cell Communication and Signaling, Jan 2022. URL: https://doi.org/10.1186/s12964-021-00811-1, doi:10.1186/s12964-021-00811-1. This article has 32 citations and is from a peer-reviewed journal.
(pustelny2022mechanismofmyd88s pages 9-11): Katarzyna Pustelny, Katarzyna Kuska, Andrzej Gorecki, Bogdan Musielak, Ewelina Dobosz, Benedykt Wladyka, Joanna Koziel, Anna Czarna, Tad Holak, and Grzegorz Dubin. Mechanism of myd88s mediated signal termination. Cell Communication and Signaling, Jan 2022. URL: https://doi.org/10.1186/s12964-021-00811-1, doi:10.1186/s12964-021-00811-1. This article has 32 citations and is from a peer-reviewed journal.
(bhatt2024structuralcharacterizationof pages 2-3): Akansha Bhatt, Biswa P. Mishra, Weixi Gu, Mitchell Sorbello, Hongyi Xu, Thomas Ve, and Bostjan Kobe. Structural characterization of tir-domain signalosomes through a combination of structural biology approaches. IUCrJ, 11:695-707, Aug 2024. URL: https://doi.org/10.1107/s2052252524007693, doi:10.1107/s2052252524007693. This article has 15 citations and is from a peer-reviewed journal.
(bhatt2024structuralcharacterizationof pages 7-8): Akansha Bhatt, Biswa P. Mishra, Weixi Gu, Mitchell Sorbello, Hongyi Xu, Thomas Ve, and Bostjan Kobe. Structural characterization of tir-domain signalosomes through a combination of structural biology approaches. IUCrJ, 11:695-707, Aug 2024. URL: https://doi.org/10.1107/s2052252524007693, doi:10.1107/s2052252524007693. This article has 15 citations and is from a peer-reviewed journal.
(li2024microcrystalelectrondiffraction pages 1-2): Y. Li, L. C. Pacoste, W. Gu, S. J. Thygesen, K. J. Stacey, T. Ve, B. Kobe, H. Xu, and J. D. Nanson. Microcrystal electron diffraction structure of toll-like receptor 2 tir-domain-nucleated myd88 tir-domain higher-order assembly. Acta Crystallographica Section D: Structural Biology, 80:699-712, Sep 2024. URL: https://doi.org/10.1107/s2059798324008210, doi:10.1107/s2059798324008210. This article has 5 citations.
(li2024microcrystalelectrondiffraction pages 8-11): Y. Li, L. C. Pacoste, W. Gu, S. J. Thygesen, K. J. Stacey, T. Ve, B. Kobe, H. Xu, and J. D. Nanson. Microcrystal electron diffraction structure of toll-like receptor 2 tir-domain-nucleated myd88 tir-domain higher-order assembly. Acta Crystallographica Section D: Structural Biology, 80:699-712, Sep 2024. URL: https://doi.org/10.1107/s2059798324008210, doi:10.1107/s2059798324008210. This article has 5 citations.
(vegivinti2023roleofinnate pages 1-3): Charan Thej Reddy Vegivinti, Praneeth Reddy Keesari, Sindhusha Veeraballi, Catarina Maria Pina Martins Maia, Ansh Krishnachandra Mehta, Rohit Reddy Lavu, Rahul Kumar Thakur, Sri Harsha Tella, Riya Patel, Venkata Kiranmayi Kakumani, Yashwitha Sai Pulakurthi, Srinivas Aluri, Ritesh Kumar Aggarwal, Nandini Ramachandra, Rongbao Zhao, Srabani Sahu, Aditi Shastri, and Amit Verma. Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and aml: a narrative review. Experimental Hematology & Oncology, Jul 2023. URL: https://doi.org/10.1186/s40164-023-00422-1, doi:10.1186/s40164-023-00422-1. This article has 52 citations and is from a peer-reviewed journal.
(minderman2023theoncogenichuman pages 8-9): Marthe Minderman, Hildo Lantermans, Carmen van der Zwaan, Arie J. Hoogendijk, Maartje van den Biggelaar, Marie José Kersten, Marcel Spaargaren, and Steven T. Pals. The oncogenic human b-cell lymphoma myd88 l265p mutation genocopies activation by phosphorylation at the toll/interleukin-1 receptor (tir) domain. Blood Cancer Journal, Aug 2023. URL: https://doi.org/10.1038/s41408-023-00896-6, doi:10.1038/s41408-023-00896-6. This article has 17 citations and is from a domain leading peer-reviewed journal.
(pustelny2022mechanismofmyd88s pages 12-14): Katarzyna Pustelny, Katarzyna Kuska, Andrzej Gorecki, Bogdan Musielak, Ewelina Dobosz, Benedykt Wladyka, Joanna Koziel, Anna Czarna, Tad Holak, and Grzegorz Dubin. Mechanism of myd88s mediated signal termination. Cell Communication and Signaling, Jan 2022. URL: https://doi.org/10.1186/s12964-021-00811-1, doi:10.1186/s12964-021-00811-1. This article has 32 citations and is from a peer-reviewed journal.
(saikh2024targetingmyeloiddifferentiation pages 2-4): Kamal U. Saikh, Khairul Anam, Halima Sultana, Rakin Ahmed, Simran Kumar, Sanjay Srinivasan, and Hafiz Ahmed. Targeting myeloid differentiation primary response protein 88 (myd88) and galectin-3 to develop broad-spectrum host-mediated therapeutics against sars-cov-2. International Journal of Molecular Sciences, 25(15):8421, Aug 2024. URL: https://doi.org/10.3390/ijms25158421, doi:10.3390/ijms25158421. This article has 9 citations.
(pereira2023regulationofinnate pages 6-7): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 164 citations and is from a peer-reviewed journal.
(pustelny2022mechanismofmyd88s pages 11-12): Katarzyna Pustelny, Katarzyna Kuska, Andrzej Gorecki, Bogdan Musielak, Ewelina Dobosz, Benedykt Wladyka, Joanna Koziel, Anna Czarna, Tad Holak, and Grzegorz Dubin. Mechanism of myd88s mediated signal termination. Cell Communication and Signaling, Jan 2022. URL: https://doi.org/10.1186/s12964-021-00811-1, doi:10.1186/s12964-021-00811-1. This article has 32 citations and is from a peer-reviewed journal.
(rughetti2024imperativeroleof pages 2-3): Aurelia Rughetti, Shreya Bharti, Rajkumar Savai, Spyridoula Barmpoutsi, Andreas Weigert, Rajat Atre, Faaiza Siddiqi, Rahul Sharma, Rakhi Khabiya, Nik Hirani, and Mirza S Baig. Imperative role of adaptor proteins in macrophage toll-like receptor signaling pathways. Future science OA, 10 1:2387961, Sep 2024. URL: https://doi.org/10.1080/20565623.2024.2387961, doi:10.1080/20565623.2024.2387961. This article has 3 citations.
(pereira2023regulationofinnate pages 12-12): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 164 citations and is from a peer-reviewed journal.
(bhatt2024structuralcharacterizationof pages 5-7): Akansha Bhatt, Biswa P. Mishra, Weixi Gu, Mitchell Sorbello, Hongyi Xu, Thomas Ve, and Bostjan Kobe. Structural characterization of tir-domain signalosomes through a combination of structural biology approaches. IUCrJ, 11:695-707, Aug 2024. URL: https://doi.org/10.1107/s2052252524007693, doi:10.1107/s2052252524007693. This article has 15 citations and is from a peer-reviewed journal.
(li2024microcrystalelectrondiffraction pages 5-8): Y. Li, L. C. Pacoste, W. Gu, S. J. Thygesen, K. J. Stacey, T. Ve, B. Kobe, H. Xu, and J. D. Nanson. Microcrystal electron diffraction structure of toll-like receptor 2 tir-domain-nucleated myd88 tir-domain higher-order assembly. Acta Crystallographica Section D: Structural Biology, 80:699-712, Sep 2024. URL: https://doi.org/10.1107/s2059798324008210, doi:10.1107/s2059798324008210. This article has 5 citations.
(bhatt2024structuralcharacterizationof pages 8-10): Akansha Bhatt, Biswa P. Mishra, Weixi Gu, Mitchell Sorbello, Hongyi Xu, Thomas Ve, and Bostjan Kobe. Structural characterization of tir-domain signalosomes through a combination of structural biology approaches. IUCrJ, 11:695-707, Aug 2024. URL: https://doi.org/10.1107/s2052252524007693, doi:10.1107/s2052252524007693. This article has 15 citations and is from a peer-reviewed journal.
(saikh2024targetingmyeloiddifferentiation pages 4-5): Kamal U. Saikh, Khairul Anam, Halima Sultana, Rakin Ahmed, Simran Kumar, Sanjay Srinivasan, and Hafiz Ahmed. Targeting myeloid differentiation primary response protein 88 (myd88) and galectin-3 to develop broad-spectrum host-mediated therapeutics against sars-cov-2. International Journal of Molecular Sciences, 25(15):8421, Aug 2024. URL: https://doi.org/10.3390/ijms25158421, doi:10.3390/ijms25158421. This article has 9 citations.
(bagratuni2023myd88wildtype pages 1-2): Tina Bagratuni, Alexandra Papadimou, Kostantina Taouxi, Meletios A. Dimopoulos, and Efstathios Kastritis. Myd88 wild type in igm monoclonal gammopathies: from molecular mechanisms to clinical challenges. Hemato, 4:259-272, Sep 2023. URL: https://doi.org/10.3390/hemato4030021, doi:10.3390/hemato4030021. This article has 5 citations.
(bagratuni2023myd88wildtype pages 4-5): Tina Bagratuni, Alexandra Papadimou, Kostantina Taouxi, Meletios A. Dimopoulos, and Efstathios Kastritis. Myd88 wild type in igm monoclonal gammopathies: from molecular mechanisms to clinical challenges. Hemato, 4:259-272, Sep 2023. URL: https://doi.org/10.3390/hemato4030021, doi:10.3390/hemato4030021. This article has 5 citations.
(tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 7-9): S TU, J YANG, MIN LI, and KUI SONG. Lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a patient with hemophagocytic syndrome. Unknown journal, 2024.
(bagratuni2023myd88wildtype pages 2-4): Tina Bagratuni, Alexandra Papadimou, Kostantina Taouxi, Meletios A. Dimopoulos, and Efstathios Kastritis. Myd88 wild type in igm monoclonal gammopathies: from molecular mechanisms to clinical challenges. Hemato, 4:259-272, Sep 2023. URL: https://doi.org/10.3390/hemato4030021, doi:10.3390/hemato4030021. This article has 5 citations.
(tu2024lymphoplasmacyticlymphomawaldenströmmacroglobulinemia pages 9-11): S TU, J YANG, MIN LI, and KUI SONG. Lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a patient with hemophagocytic syndrome. Unknown journal, 2024.
(lemasson2023bcellspecificexpression pages 1-6): Quentin Lemasson, Ophélie Téteau, Mina Chabaud, Laurie Jeanson, Jean Feuillard, and Christelle Vincent-Fabert. B-cell specific expression of the murine myd88l252p mutation correlates with the establishment of an immunosuppressive microenvironnement in waldenström macroglobulinemia lymphoplasmacytic lymphoma. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2023.09.28.559899, doi:10.1101/2023.09.28.559899. This article has 0 citations.